Lisa Cook sues Trump over firing attempt, emergency hearing set
Haleon plc (LSE/NYSE:HLN), a global consumer health company, disclosed a transaction by Marie-Anne Aymerich, an Independent (LON:IOG) Non-Executive Director and Person Discharging Managerial Responsibilities (PDMR), in a filing with the U.S. Securities and Exchange Commission today. Aymerich purchased 21,300 ordinary shares at a price of £4.051 each on May 9, 2025, as per the notification received by the company on May 13, 2025. The transaction took place on the London Stock Exchange (LON:LSEG).
This disclosure is in accordance with the UK Market Abuse Regulation, which mandates public notification of transactions by PDMRs. The transaction represents a single purchase of shares, with no aggregated transactions reported.
Haleon, known for its trusted brands such as Advil, Centrum, and Sensodyne, focuses on delivering everyday health products to consumers. The company’s portfolio covers major categories including Oral Health, Pain Relief, and Vitamins, Minerals, and Supplements (VMS), among others.
The information provided in this news article is based on Haleon plc’s recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.